Annovis Bio (NYSE:ANVS) shares fell round 19% premarket on Monday after the corporate priced a securities providing to boost $21M.
The sale includes 5.25M shares of widespread inventory and warrants to buy 5.25M shares, issued at a mixed public providing value of $4.00 per share.